NextCure (NXTC) Competitors $5.13 +0.02 (+0.39%) Closing price 08/22/2025 03:52 PM EasternExtended Trading$5.12 -0.01 (-0.19%) As of 08/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. UNCY, DTIL, PDSB, ELYM, KLRS, ANVS, PYRGF, PRLD, CVM, and INKTShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Unicycive Therapeutics (UNCY), Precision BioSciences (DTIL), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), Kalaris Therapeutics (KLRS), Annovis Bio (ANVS), PyroGenesis Canada (PYRGF), Prelude Therapeutics (PRLD), CEL-SCI (CVM), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Unicycive Therapeutics Precision BioSciences PDS Biotechnology Eliem Therapeutics Kalaris Therapeutics Annovis Bio PyroGenesis Canada Prelude Therapeutics CEL-SCI MiNK Therapeutics NextCure (NASDAQ:NXTC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Do insiders & institutionals hold more shares of NXTC or UNCY? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 17.9% of NextCure shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate NXTC or UNCY? NextCure currently has a consensus target price of $25.50, suggesting a potential upside of 397.08%. Unicycive Therapeutics has a consensus target price of $60.00, suggesting a potential upside of 1,328.57%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility and risk, NXTC or UNCY? NextCure has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Is NXTC or UNCY more profitable? NextCure's return on equity of -106.62% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -106.62% -85.20% Unicycive Therapeutics N/A -243.13%-119.46% Which has better valuation & earnings, NXTC or UNCY? Unicycive Therapeutics has higher revenue and earnings than NextCure. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$25.82-0.20Unicycive Therapeutics$680K109.08-$36.73M-$4.12-1.02 Does the media refer more to NXTC or UNCY? In the previous week, Unicycive Therapeutics had 28 more articles in the media than NextCure. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 0 mentions for NextCure. Unicycive Therapeutics' average media sentiment score of 0.28 beat NextCure's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NextCure Neutral Unicycive Therapeutics Neutral SummaryUnicycive Therapeutics beats NextCure on 9 of the 14 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.68M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-0.2021.1431.2526.05Price / SalesN/A345.39433.91193.97Price / CashN/A43.1937.7358.48Price / Book0.438.129.536.61Net Income-$55.65M-$54.72M$3.26B$265.65M7 Day Performance0.69%2.62%2.13%2.03%1 Month Performance-1.35%2.68%2.80%-0.31%1 Year Performance-73.45%10.93%30.68%19.06% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.092 of 5 stars$5.13+0.4%$25.50+397.1%-72.9%$13.68MN/A-0.2090UNCYUnicycive Therapeutics2.6176 of 5 stars$4.01-2.0%$60.00+1,396.3%+10.5%$51.70M$680K-0.799Trending NewsAnalyst DowngradeDTILPrecision BioSciences4.0691 of 5 stars$4.35-0.7%$47.00+980.5%-49.0%$51.63M$68.70M-0.49200Positive NewsPDSBPDS Biotechnology2.1695 of 5 stars$1.08-2.7%$9.00+733.3%-63.9%$50.74MN/A-1.1520ELYMEliem TherapeuticsN/A$1.70+1.2%N/A-62.3%$50.58MN/A-3.219News CoveragePositive NewsKLRSKalaris Therapeutics1.2851 of 5 stars$2.66-0.4%$3.00+12.8%N/A$49.94MN/A0.00110ANVSAnnovis Bio2.5185 of 5 stars$2.82+10.6%$18.00+538.3%-74.0%$49.69MN/A-1.313PYRGFPyroGenesis CanadaN/A$0.26-5.4%N/A-63.8%$49.68M$9.14M-4.4290PRLDPrelude Therapeutics2.8083 of 5 stars$0.83-3.6%$4.50+444.1%-77.8%$48.42M$7M-0.49120CVMCEL-SCI1.3441 of 5 stars$7.03-5.5%N/A-71.5%$48.38MN/A-14.6543Positive NewsINKTMiNK Therapeutics2.7856 of 5 stars$12.22+1.3%$37.50+206.9%+84.5%$48.07MN/A-4.8530Trending NewsAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies UNCY Competitors DTIL Competitors PDSB Competitors ELYM Competitors KLRS Competitors ANVS Competitors PYRGF Competitors PRLD Competitors CVM Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access